Valuation: OLIPASS Corporation

Market Cap 26.53B 18.77M 16.2M 15.2M 13.84M 26.03M 1.79B 26.39M 178M 69.82M 899M 70.45M 68.93M 2.99B P/E 2021
-10.8x
P/E 2022 -7.66x
Enterprise Value 20.34B 14.38M 12.42M 11.65M 10.61M 19.95M 1.38B 20.23M 137M 53.51M 689M 54M 52.83M 2.29B EV / Sales 2021
295x
EV / Sales 2022 79x
Free-Float
48.85%
Yield 2021 *
-
Yield 2022 -
3 years 1,568
Extreme 1568
34,500
5 years 1,568
Extreme 1568
143,000
10 years 1,568
Extreme 1568
240,666.67
Manager TitleAgeSince
Chief Executive Officer 54 2025-05-21
Corporate Officer/Principal 34 2024-11-27
Comptroller/Controller/Auditor 67 2025-03-30
Director TitleAgeSince
Director/Board Member 54 2024-11-27
Director/Board Member 34 2024-11-27
Director/Board Member 66 -
Change 5-day change 1-year change 3-year change Capi.($)
-13.92%-.--%-.--%-90.93% 9.53M
+4.80%+3.44%+70.64%+109.32% 70.07B
+17.12%+11.50%+54.42%+87.30% 52.87B
+3.70%-4.77%+0.41%+484.07% 27.02B
+4.77%+5.18%+56.00%+20.75% 23.61B
-1.60%-1.29%-19.31%-19.10% 23.38B
-6.00%+6.02%+244.39%+430.80% 19.43B
+3.80%+5.62%+40.50%-15.26% 18.75B
+3.92%+3.03%+21.87%+560.00% 15.85B
+2.11%-1.21%+36.57%+149.14% 12.7B
Average +1.90%-4.46%+50.55%+171.61% 26.37B
Weighted average by Cap. +5.55%+2.25%+56.99%+167.83%

Financials

2021 2022
Net sales 852M 602K 520K 488K 444K 836K 57.6M 847K 5.72M 2.24M 28.86M 2.26M 2.21M 96M 2.3B 1.62M 1.4M 1.32M 1.2M 2.25M 155M 2.28M 15.42M 6.04M 77.79M 6.1M 5.97M 259M
Net income -25.13B -17.78M -15.35M -14.4M -13.11M -24.66M -1.7B -25M -169M -66.14M -852M -66.75M -65.3M -2.83B -24.17B -17.09M -14.76M -13.84M -12.61M -23.71M -1.63B -24.04M -162M -63.6M -819M -64.18M -62.79M -2.72B
Net Debt -18.29B -12.94M -11.17M -10.48M -9.54M -17.94M -1.24B -18.19M -123M -48.13M -620M -48.57M -47.52M -2.06B -6.2B -4.38M -3.78M -3.55M -3.23M -6.08M -419M -6.16M -41.6M -16.3M -210M -16.45M -16.09M -698M
Logo OLIPASS Corporation
OliPass Corp is a Korea-based company principally engaged in the research and development of biopharmaceuticals. The Company is mainly engaged in the development of non-opioid analgesics, amyotrophic lateral sclerosis (ALS) treatments, therapies for age-related macular degeneration, and diabetic retinopathy. In addition, the Company researches, develops and sells functional cosmetics through artificial gene platform technology.
Employees
-
  1. Stock Market
  2. Stocks
  3. A244460 Stock